Joseph Schlessinger

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc On the nature of low- and high-affinity EGF receptors on living cells
    Ferruh Ozcan
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 103:5735-40. 2006
  2. pmc Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice
    Hava Gil-Henn
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06511, USA
    J Cell Biol 178:1053-64. 2007
  3. pmc The genesis of Zelboraf: targeting mutant B-Raf in melanoma
    Matthew J Davis
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Cell Biol 199:15-9. 2012
  4. ncbi request reprint Nuclear signaling by receptor tyrosine kinases: the first robin of spring
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Cell 127:45-8. 2006
  5. ncbi request reprint Common and distinct elements in cellular signaling via EGF and FGF receptors
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Science 306:1506-7. 2004
  6. ncbi request reprint A solid base for assaying protein kinase activity
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Nat Biotechnol 20:232-3. 2002
  7. ncbi request reprint SH2 and PTB domains in tyrosine kinase signaling
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Sci STKE 2003:RE12. 2003
  8. ncbi request reprint Signal transduction. Autoinhibition control
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Science 300:750-2. 2003
  9. ncbi request reprint Ligand-induced, receptor-mediated dimerization and activation of EGF receptor
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Cell 110:669-72. 2002
  10. ncbi request reprint The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors
    Irit Lax
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Mol Cell 10:709-19. 2002

Research Grants

  1. Docking protein FRS2 in FGF signaling
    Joseph Schlessinger; Fiscal Year: 2004
  2. FGF RECEPTOR SIGNALING IN BONE DEVELOPMENT
    Joseph Schlessinger; Fiscal Year: 2009
  3. Docking protein FRS2 in FGF signaling
    Joseph Schlessinger; Fiscal Year: 2007
  4. FGF RECEPTOR SIGNALING IN BONE DEVELOPMENT
    Joseph Schlessinger; Fiscal Year: 2007
  5. Docking protein FRS2 in FGF signaling
    Joseph Schlessinger; Fiscal Year: 2006
  6. FGF RECEPTOR SIGNALING IN BONE DEVELOPMENT
    Joseph Schlessinger; Fiscal Year: 2006
  7. Docking protein FRS2 in FGF signaling
    Joseph Schlessinger; Fiscal Year: 2005

Collaborators

Detail Information

Publications53

  1. pmc On the nature of low- and high-affinity EGF receptors on living cells
    Ferruh Ozcan
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 103:5735-40. 2006
    ....
  2. pmc Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice
    Hava Gil-Henn
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06511, USA
    J Cell Biol 178:1053-64. 2007
    ..These experiments underscore an important role of Pyk2 in microtubule-dependent podosome organization, bone resorption, and other osteoclast functions...
  3. pmc The genesis of Zelboraf: targeting mutant B-Raf in melanoma
    Matthew J Davis
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Cell Biol 199:15-9. 2012
    ..A structure-guided drug discovery approach enabled the development of Zelboraf, a targeted inhibitor of oncogenic B-Raf. This drug has been used successfully in the clinic to treat metastatic melanoma patients harboring B-Raf mutations...
  4. ncbi request reprint Nuclear signaling by receptor tyrosine kinases: the first robin of spring
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Cell 127:45-8. 2006
    ..The fragment forms a complex with the adaptor TAB2 and the corepressor N-CoR and transits to the nucleus, where it represses transcription of genes that promote the formation of astrocytes...
  5. ncbi request reprint Common and distinct elements in cellular signaling via EGF and FGF receptors
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Science 306:1506-7. 2004
    ..The differential circuitry of the intracellular networks that are activated by EGFR and FGFR may affect signal specificity and physiological responses...
  6. ncbi request reprint A solid base for assaying protein kinase activity
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Nat Biotechnol 20:232-3. 2002
  7. ncbi request reprint SH2 and PTB domains in tyrosine kinase signaling
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Sci STKE 2003:RE12. 2003
    ....
  8. ncbi request reprint Signal transduction. Autoinhibition control
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Science 300:750-2. 2003
  9. ncbi request reprint Ligand-induced, receptor-mediated dimerization and activation of EGF receptor
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Cell 110:669-72. 2002
    ..Receptor dimerization is mediated by receptor-receptor interactions in which a loop protruding from neighboring receptors mediates receptor dimerization and activation...
  10. ncbi request reprint The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors
    Irit Lax
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Mol Cell 10:709-19. 2002
    ..These experiments reveal a novel MAPK-mediated, negative feedback mechanism for control of signaling pathways that are dependent on FRS2 and a mechanism for heterologous control of signaling via FGF receptors...
  11. pmc Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane
    Leiliane P Sousa
    Departments of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 109:4419-24. 2012
    ....
  12. pmc RAC1P29S is a spontaneously activating cancer-associated GTPase
    Matthew J Davis
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 110:912-7. 2013
    ..The melanoma RAC1(P29S) gain-of-function point mutation therefore represents a previously undescribed class of cancer-related GTPase activity...
  13. pmc Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation
    Erin D Lew
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 104:19802-7. 2007
    ....
  14. pmc The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway
    Dawn R Mattoon
    Department of Pharmacology, Yale University School of Medicine, PO Box 208066, New Haven, CT 06520 8066, USA
    BMC Biol 2:24. 2004
    ..As the autophosphorylation sites on EGF-receptor (EGFR) do not include canonical PI-3 kinase binding sites, it is thought that EGF stimulation of PI-3 kinase and its downstream effector Akt is mediated by an indirect mechanism...
  15. pmc Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells
    Jae Hyun Bae
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 107:2866-71. 2010
    ..The experiments presented in this report provide the molecular basis underlying the control of transphosphorylation of FGF receptors and other receptor tyrosine kinases...
  16. pmc The docking protein Gab1 is an essential component of an indirect mechanism for fibroblast growth factor stimulation of the phosphatidylinositol 3-kinase/Akt antiapoptotic pathway
    Betty Lamothe
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar St, SHM B 295, New Haven, CT 06520, USA
    Mol Cell Biol 24:5657-66. 2004
    ....
  17. pmc A structure-based model for ligand binding and dimerization of EGF receptors
    Peter Klein
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 101:929-34. 2004
    ..However, these extended receptors do not correspond directly with the "high-affinity" EGF-binding sites seen in EGF-binding studies on intact cells...
  18. pmc The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations
    Erin D Lew
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Sci Signal 2:ra6. 2009
    ..We propose that disrupted stepwise activation of tyrosine autophosphorylation caused by oncogenic and other activating FGFR mutations may lead to aberrant activation of and assembly of signaling molecules by the activated receptor...
  19. pmc Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling
    Yan Yang
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 107:1906-11. 2010
    ..It also reveals a conserved mechanism for RTK activation and a novel target for pharmacological intervention of pathologically activated RTKs...
  20. pmc Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region
    Andrey V Reshetnyak
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520
    Proc Natl Acad Sci U S A 110:17832-7. 2013
    ..These antibodies represent a unique therapeutic approach and a step toward the development of "naked" or toxin-conjugated KIT antibodies for the treatment of KIT-driven cancers. ..
  21. pmc Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization
    Yan Yang
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 105:7681-6. 2008
    ..Moreover, PDGFRbeta dimerization is necessary but not sufficient for tyrosine kinase activation...
  22. ncbi request reprint Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor
    Satoru Yuzawa
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Cell 130:323-34. 2007
    ....
  23. pmc Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening
    Krishna P Ravindranathan
    Department of Chemistry, Yale University, New Haven, Connecticut 06520, USA
    J Med Chem 53:1662-72. 2010
    ..The study also illustrates complexities associated with the choice of protein structures for docking, possible use of multiple kinase structures to seek selectivity, and hit identification...
  24. pmc Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at arrested endocytic clathrin-coated pits of cells that lack dynamin
    Hongying Shen
    Department of Cell Biology, Howard Hughes Medical Institute, Program in Cellular Neuroscience, Neurodegeneration and Repair, and Kavli Institute for Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA
    Mol Biol Cell 22:493-502. 2011
    ..These findings reveal a link between progression of clathrin-coated pits to endocytic vesicles and an activation-deactivation cycle of Ack...
  25. pmc Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers
    Yarden Opatowsky
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520
    Proc Natl Acad Sci U S A 111:1772-7. 2014
    ....
  26. pmc Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli
    Maria L Galisteo
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 103:9796-801. 2006
    ..These experiments suggest a functional role for Ack as an early transducer of multiple extracellular stimuli...
  27. doi request reprint The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site
    Jae Hyun Bae
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Cell 138:514-24. 2009
    ..These experiments reveal a mechanism for how SH2 domain selectivity is regulated in vivo to mediate a specific cellular process...
  28. ncbi request reprint Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases
    Jae Hyun Bae
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520 8066, USA
    Mol Cells 29:443-8. 2010
    ..These studies demonstrate that asymmetric dimer formation is as a common phenomenon critical for activation and autophosphorylation of RTKs...
  29. pmc The docking protein FRS2α is a critical regulator of VEGF receptors signaling
    Pei Yu Chen
    Yale Cardiovascular Research Center, Department of Internal Medicine, and Departments of Surgery, Pharmacology, and Cell Biology, Yale University School of Medicine, New Haven, CT 06520
    Proc Natl Acad Sci U S A 111:5514-9. 2014
    ..We conclude that FRS2α is a previously unidentified component of VEGF receptors signaling. ..
  30. pmc Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate
    Byung Hak Ha
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 109:16107-12. 2012
    ..Finally, we find Src SH3, but not β-PIX SH3, can activate PAK4. We provide a unique understanding for type II PAK regulation...
  31. ncbi request reprint FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts
    Noriko Gotoh
    Department of Pharmacology, Yale University School of Medicine, Sterling Hall of Medicine, 333 Cedar Street, B 204, New Haven, CT 06520, USA
    FEBS Lett 564:14-8. 2004
    ..We propose that the FRS2 family proteins have distinct roles in vivo through activation of common signaling proteins including MAP kinase...
  32. doi request reprint Crystal structures of free and ligand-bound focal adhesion targeting domain of Pyk2
    James Lulo
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Biochem Biophys Res Commun 383:347-52. 2009
    ....
  33. ncbi request reprint [Structural biology of receptor tyrosine kinase kit]
    Satornu Yuzawa
    Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Seikagaku 80:94-104. 2008
  34. pmc The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function
    Dawn Mattoon
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 101:923-8. 2004
    ..Furthermore, the autoinhibition conferred by the tethered configuration of the extracellular ligand-binding domain provides only a limited control of EGFR function...
  35. pmc Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway
    Imad Shams
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Mol Cell Biol 27:6903-12. 2007
    ....
  36. ncbi request reprint All signaling is local?
    Joseph Schlessinger
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA
    Mol Cell 10:218-9. 2002
    ..Recent studies have visualized the spatio-temporal pattern of EGF signaling, indicating that receptor density is an important factor in the mechanism of lateral propagation of local EGF signaling...
  37. ncbi request reprint Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction
    Cristina M Furdui
    Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Mol Cell 21:711-7. 2006
    ....
  38. pmc FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl
    Andy Wong
    Department of Pharmacology, Sterling Hall of Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 99:6684-9. 2002
    ..However, the partial inhibition of FGF receptor down-regulation in FRS2 alpha-/- cells indicates that the attenuation of signaling by FGF receptor is regulated by redundant or multiple mechanisms...
  39. pmc FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma
    Yaron Hadari
    Kolltan Pharmaceuticals Inc, New Haven, Connecticut, USA
    J Clin Invest 119:1077-9. 2009
    ..These results suggest that clinical development of anti-FGFR3 mAbs should be considered for targeted therapy of cancer and other diseases...
  40. pmc Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
    Michael Krauthammer
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Nat Genet 44:1006-14. 2012
    ..These findings raise the possibility that pharmacological inhibition of downstream effectors of RAC1 signaling could be of therapeutic benefit...
  41. ncbi request reprint A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions
    Sheila Harroch
    Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Nat Genet 32:411-4. 2002
    ..These results support a role for Ptprz in oligodendrocyte survival and in recovery from demyelinating disease...
  42. pmc Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface
    Jessica P Dawson
    Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, 19104 6059, USA
    Mol Cell Biol 25:7734-42. 2005
    ..Our data also suggest that similar conformational changes may determine the specificity of ErbB receptor homo- versus heterodimerization...
  43. pmc Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity
    Shaun K Olsen
    Departments of Pharmacology and Microbiology, New York University School of Medicine, New York, NY 10016, USA
    Proc Natl Acad Sci U S A 101:935-40. 2004
    ..Importantly, comparison of the three FGF1-FGFR structures shows that the flexibility of the betaC'-betaE loop is a major determinant of ligand-binding specificity and promiscuity...
  44. pmc Receptor protein tyrosine phosphatase gamma is a marker for pyramidal cells and sensory neurons in the nervous system and is not necessary for normal development
    Smaragda Lamprianou
    Institut Pasteur, Department of Neuroscience, 25 rue du Dr Roux, 75724 Paris, France
    Mol Cell Biol 26:5106-19. 2006
    ..An initial behavioral analysis showed minor changes in the RPTPgamma-null mice...
  45. pmc A putative molecular-activation switch in the transmembrane domain of erbB2
    Sarel J Fleishman
    Department of Biochemistry, The George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 69987, Israel Middle East
    Proc Natl Acad Sci U S A 99:15937-40. 2002
    ....
  46. pmc Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains
    Hideyuki Yokote
    Department of Molecular Cell Biology, Institute of Advanced Medicine, Wakayama Medical University, 811 1 Kimiidera, Wakayama 641 8509, Japan
    Proc Natl Acad Sci U S A 102:18866-71. 2005
    ....
  47. ncbi request reprint A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design
    Graeme L Card
    Plexxikon Inc, 91 Bolivar Dr, Berkeley, California 94710, USA
    Nat Biotechnol 23:201-7. 2005
    ....
  48. ncbi request reprint A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases
    Kam Y J Zhang
    Plexxikon Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Mol Cell 15:279-86. 2004
    ..The structural understanding of nucleotide binding enables the design of new PDE inhibitors that may treat diseases in which cyclic nucleotides play a critical role...
  49. ncbi request reprint The biochemical response of the heart to hypertension and exercise
    Tetsuro Wakatsuki
    Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Washington University Medical Center, Campus Box 8231, 660 South Euclid Avenue, St Louis, MI 63110 1093, USA
    Trends Biochem Sci 29:609-17. 2004
    ..Despite this progress, the mechanisms that activate fibroblasts to cause fibrosis and those that differentiate between exercise and hypertension to produce physiological and pathological responses, respectively, remain to be established...
  50. ncbi request reprint Mutations in different components of FGF signaling in LADD syndrome
    Edyta Rohmann
    Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany
    Nat Genet 38:414-7. 2006
    ..These findings increase the spectrum of anomalies associated with abnormal FGF signaling...
  51. ncbi request reprint Structural basis for the activity of drugs that inhibit phosphodiesterases
    Graeme L Card
    Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Structure 12:2233-47. 2004
    ..These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases...
  52. pmc Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    James Tsai
    Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Proc Natl Acad Sci U S A 105:3041-6. 2008
    ....
  53. ncbi request reprint 'Tuning' of type I interferon-induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages
    Lu Wang
    Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, New York 10021, USA
    Nat Immunol 9:186-93. 2008
    ..Our results associate Pyk2 and Jak kinases with the linkage of signals emanating from cytokine and heterologous ITAM-dependent receptors...

Research Grants10

  1. Docking protein FRS2 in FGF signaling
    Joseph Schlessinger; Fiscal Year: 2004
    ..abstract_text> ..
  2. FGF RECEPTOR SIGNALING IN BONE DEVELOPMENT
    Joseph Schlessinger; Fiscal Year: 2009
    ....
  3. Docking protein FRS2 in FGF signaling
    Joseph Schlessinger; Fiscal Year: 2007
    ..abstract_text> ..
  4. FGF RECEPTOR SIGNALING IN BONE DEVELOPMENT
    Joseph Schlessinger; Fiscal Year: 2007
    ....
  5. Docking protein FRS2 in FGF signaling
    Joseph Schlessinger; Fiscal Year: 2006
    ..abstract_text> ..
  6. FGF RECEPTOR SIGNALING IN BONE DEVELOPMENT
    Joseph Schlessinger; Fiscal Year: 2006
    ....
  7. Docking protein FRS2 in FGF signaling
    Joseph Schlessinger; Fiscal Year: 2005
    ..abstract_text> ..